Physician profile
Robert H Ewing
NPI 1548265267
$1,642.09
in general payments reported to CMS, 2019-2025
13 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $18.37 · 2021: $206 · 2022: $121 · 2023: $122 · 2024: $57.61 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583 · Entertainment: $23.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.76 |
| Entertainment | $23.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $647.32 | 2019-2024 | Clareon, Rocklatan |
| Amgen INC. | $281.01 | 2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $184.12 | 2019-2021 | |
| Glaukos Corporation | $146.21 | 2025 | Istent Infinite, Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $107.05 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $80.27 | 2019-2023 | Tecnis Simplicity, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $58.41 | 2019-2023 | Cequa |
| Horizon Therapeutics Plc | $35.66 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $25.47 | 2023 | Xeomin |
| Optos, INC. | $23.78 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $22.82 | 2022 | |
| Bausch & Lomb Americas INC. | $17.11 | 2024 | Vyzulta, Miebo |
| Abbvie INC. | $12.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ewing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.